Neoadjuvant Immunotherapy in Head and Neck Cancer, Sarcoma and Cutaneous Malignancies

Recent landmark studies in melanoma, cutaneous squamous cell carcinoma (cSCC), head and neck cancer (HNC) and sarcoma have established neoadjuvant immune therapy as a potential standard of care for patients with locally advanced cancers. Radiation oncologists need to be aware of this new paradigm, in part because it has important implications for radiation therapy. In melanoma, neoadjuvant immune therapy was found to be superior to adjuvant immune therapy in recent randomized studies. In cSCC, pathologic response following neoadjuvant immune therapy can potentially help inform whether adjuvant treatment is needed. In mucosal HNC, the KEYNOTE-689 study will likely establish neoadjuvant immune therapy as a new standard of care approach. According to this study, patients who receive preoperative immune therapy may also benefit from further immune therapy administered during adjuvant radiation. Preoperative radiation combined with immune therapy could potentially improve pathologic response and enhance outcomes; this strategy has been tested in HNC and recently found to be beneficial in soft tissue sarcoma. The goal of this activity is to inform the radiation oncology community of these recent, and in many cases, practice changing, data to help inform practice and future research. In addition to reviewing current data and standards of care, we also address relevant topics of interest such as: the immunologic rationale for neoadjuvant immune therapy; relevant biomarkers to predict response; the use of pathologic response as a surrogate endpoint; and how neoadjuvant immune therapy may impact the landscape of adjuvant treatment including radiation therapy.

Topics:

  1. Neoadjuvant Immune Therapy for Cutaneous Malignancies
    Christopher A. Barker, MD
  2. Neoadjuvant Immunotherapy in Mucosal Head and Neck Cancer  
    Kevin J. Contrera, MD, MPH
  3. Neoadjuvant Radiation/Immunotherapy in HNSCC
    Marka R. Crittenden, MD, PhD
  4. Neoadjuvant Pembrolizumab and Radiation Therapy for Soft Tissue Sarcoma of the Extremity
    Yvonne Marie Mowery, MD, PhD, BS
  5. Q and A
    Vinita Takiar, MD, PhD - Moderator
    Full Panel

This activity is available from January 6, 2026, through 11:59 p.m. Eastern time on January 5, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, pathologists, radiation biologists, radiation therapists, immunologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the data supporting neoadjuvant immune therapy and discuss the rationale for this approach.
  • Describe the potential implication neoadjuvant immunotherapy or immunotherapy/radiation combinations has on adjuvant treatment recommendations.
  • Identify ongoing and future research exploring neoadjuvant immunotherapy such as neoadjuvant immunotherapy/radiotherapy combinations.

Course summary

Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
01/06/2026
Course expires: 
01/05/2028
Cost:
$149.00
Rating: 
0
  • Lin L. Zhu, MD, PhD, is employed by UT Southwestern Medical Center. 
  • Vinita Takiar, MD, PhD, is employed by University of Cincinnati College of Medicine and the Cincinnati VA Medical Center. Dr. Takiar receives grant/research funding from the NIH and the Veterans Affairs Medical Center. Dr. Takiar receives travel expenses from the American Board of Radiology.  
  • Christopher A. Barker, MD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Barker’s institute receives grant/research funding from Alpha Tau Medical, Amgen, Elekta, EMD Serono, National Institutes of Health and Regeneron. 
  • Kevin J. Contrera, MD, MPH, is employed by University of Pittsburgh Medical Center. Dr. Contrera has no financial relationship with ineligible companies. 
  • Marka R. Crittenden, MD, PhD, is employed by Earle A. Chiles Research Institute, Providence Cancer Institute and is a Partner with the Oregon Clinic. Dr. Crittenden has a sponsored research agreement for reagents from BMS.  
  • Yvonne Marie Mowery, MD, PhD, BS, is employed by UPMC Hillman Cancer Center. Dr. Mowery receives grant/research funding from the Damon Runyon Cancer Foundation, the John R. Flanagan Charitable Foundation, NIDCR/NIH/NCI and SU2C. Dr. Mowery receives honoraria from UpToDate.   

Planners: 

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Activity Fees

This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.

ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:

  • Academy Subscriber: $0
  • Member: $99
  • Member-in-Training / Student Member / Postdoctoral Fellow Member: $49
  • Nonmember: $149

Discounts
Please email ASTRO eLearning to inquire about the discounts below.

  • If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
  • If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.

Policies

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.